Scholarlink

Purpose <p>We investigated the persistence of medication for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) and identified baseline factors associated with treatment discontinuation in a clinical cohort of Japanese men.</p> Methods <p>We included 2500 patients between April 1, 2014 and March 31, 2015. The final analysis included 2295 patients from 30 urological hospitals. We collected baseline characteristics, including age, prostate-specific antigen (PSA) level, prostate volume (PV), International Prostate Symptom Score (IPSS), and quality-of-life (QOL) score. The type of initial medication and reasons for treatment discontinuation were recorded.</p> Results <p>The median participant age was 72 years. The median PSA level was 2.4 ng/mL, the median PV was 33 mL, the median IPSS score was 15 points, and the median QOL score was 5 points. The median time to medication discontinuation was 154 days (95% confidence interval [CI]: 132–176). Persistence rates at 1, 2, 3, 4, and 5 years were 37.3%, 29.1%, 24.2%, 20.2%, and 17.8%, respectively. The most common reason for discontinuation was loss to follow-up (71.1%). Multivariate analysis showed that younger age (70–79 vs. ≥80 years and ≤ 69 vs. ≥80 years), higher PSA level (≥ 2.4 vs. &lt;2.4 ng/mL), greater PV (≥ 33 vs. &lt;33 mL), and month of medication initiation were significantly associated with longer treatment persistence.</p> Conclusion <p>Persistence of treatment with medication for LUTS/BPH was relatively low in our cohort. Several baseline factors, including age, PSA level, PV, and the month of treatment initiation, were identified as predictors of treatment persistence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world adherence and persistence with medication among men with lower urinary tract symptoms owing to benign prostatic hyperplasia in Japan: a clinical prospective study

  • 期刊论文

  • 发表日期：

    2025年6月19日

查看全文
  • Toshiyuki Kamoto,
  • Hiromasa Tsukino

摘要

Purpose

We investigated the persistence of medication for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) and identified baseline factors associated with treatment discontinuation in a clinical cohort of Japanese men.

Methods

We included 2500 patients between April 1, 2014 and March 31, 2015. The final analysis included 2295 patients from 30 urological hospitals. We collected baseline characteristics, including age, prostate-specific antigen (PSA) level, prostate volume (PV), International Prostate Symptom Score (IPSS), and quality-of-life (QOL) score. The type of initial medication and reasons for treatment discontinuation were recorded.

Results

The median participant age was 72 years. The median PSA level was 2.4 ng/mL, the median PV was 33 mL, the median IPSS score was 15 points, and the median QOL score was 5 points. The median time to medication discontinuation was 154 days (95% confidence interval [CI]: 132–176). Persistence rates at 1, 2, 3, 4, and 5 years were 37.3%, 29.1%, 24.2%, 20.2%, and 17.8%, respectively. The most common reason for discontinuation was loss to follow-up (71.1%). Multivariate analysis showed that younger age (70–79 vs. ≥80 years and ≤ 69 vs. ≥80 years), higher PSA level (≥ 2.4 vs. <2.4 ng/mL), greater PV (≥ 33 vs. <33 mL), and month of medication initiation were significantly associated with longer treatment persistence.

Conclusion

Persistence of treatment with medication for LUTS/BPH was relatively low in our cohort. Several baseline factors, including age, PSA level, PV, and the month of treatment initiation, were identified as predictors of treatment persistence.